Methicillin-resistant Staphylococcus aureus (MRSA) is one of the pathogens driving interest in antimicrobial peptides as a fresh antibiotic class. AMPs tend to kill bacteria by disrupting membranes and hitting several targets at once, mechanisms that resistant strains have a hard time evading.
Recent work on this site has leaned on computational design. The CAMPER AI framework produced a peptide that kills MRSA persister cells, and a follow-up generated WP-CAMPER1, a 12-mer that killed MRSA at 4 µg/mL. A July 2026 Nature Communications study took a different route, describing a linear peptide of four D-tryptophan/D-arginine/D-lysine repeats that killed MRSA and Klebsiella pneumoniae in pneumonia models, resisted degradation, and helped restore sensitivity to existing antibiotics.
Stories here follow MRSA-active peptides, their design methods, and the broader push to answer antibiotic resistance with peptide chemistry. See #antimicrobial-peptides and #antibiotic-resistance.
Konkuk University researchers modeled antimicrobial peptides on a Mycobacterium tuberculosis enzyme, adenylate kinase, that recognizes both Gram-negative and Gram-positive cell-wall molecules, then added non-natural amino acids, an N-terminal fatty acid chain, and an arginine extension. The lead peptide, YK-mAK-17, killed carbapenem-resistant Acinetobacter baumannii and MRSA quickly by disrupting their membranes, showed little resistance development, and improved survival and reduced organ damage in mice with septic shock caused by either bacterium, the Journal of Medicinal Chemistry paper reports.
Two 2026 antimicrobial peptide research programs continue to press on multidrug-resistant Staphylococcus aureus. CAMPER (a mechanistic artificial intelligence system for designing peptides that target MRSA persister cells, published 2026) generated a new class of AMPs that reach the metabolically dormant persister subpopulation that survives conventional antibiotic exposure and drives biofilm relapse. Li et al. (2026) developed RFC, a self-assembling peptide that mimics the structure and function of neutrophil extracellular traps (NETs), forming nanofibrillar networks that entrap bacteria and disrupt their membranes. Separate work published this year characterized photo-responsive amyloid nanoNETs from lysozyme-derived nanofibrils that combine antibacterial activity against MRSA with promotion of tissue regeneration under near-infrared stimulation. Synergistic combinations with existing antibiotics (nisin, indolicidin, and α-MSH analogs with β-lactams) continue to show improved anti-biofilm efficacy in vitro. The programs are still preclinical but keep antimicrobial peptides in serious development at a time when the small-molecule antibiotic pipeline remains thin.
A study in Nature Communications describes a linear antimicrobial peptide built from four D-tryptophan/D-arginine/D-lysine repeats that stays stable in the body and kills multidrug-resistant bacteria, including MRSA and Klebsiella pneumoniae. In bacterial pneumonia models, the peptide acted through membrane targeting alongside DNA binding, reactive-oxygen accumulation, and ATP depletion, showed low potential to drive resistance, and helped restore sensitivity to existing antibiotics.
Fadi Shehadeh, Biswajit Mishra and collaborators published CAMPER (Constraint-driven AMP Engineering with Ranking) in Nature Communications 2026, integrating machine learning with mechanistic biological features to design peptides that target MRSA persister cells. The lead candidate, WP-CAMPER1, kills S. aureus MW2 at a minimal inhibitory concentration of 4 µg/mL. A 2% topical formulation reduced bacterial burden 2.5 log10 in a murine prophylactic skin infection model; the D-enantiomer WP-CAMPER1-d achieved 1.37 log10 reduction in established biofilm infections.
A Nature Communications paper introduces CAMPER (Constraint-driven AMP Engineering with Ranking), a mechanistic AI framework that integrates machine learning with biophysical ranking to design membrane-targeting peptides against MRSA persisters and biofilms. The framework identified WP-CAMPER1, a 12-mer peptide that kills S. aureus MW2 at an MIC of 4 µg/mL; a 2% topical formulation reduced S. aureus burden by 2.5 log10 in a murine skin infection model.